PROUD trial finds PrEP highly effective

October 16, 2014

A recommendation from the trial’s independent Data and Safety Monitoring Board has triggered changes in the trial protocol, based on evidence of efficacy.

  • Read the official statement from the trial team behind the PROUD trial of daily oral tenofovir-based PrEP among MSM in the UK.
  • Read the post on the AVAC blog.

Welcome to PrEP Watch, a clearinghouse for information on pre-exposure prophylaxis (PrEP) for HIV prevention. PrEP Watch includes information on data, additional research, cost, access and advocacy efforts in the United States and across the globe.


Resources to Understand PrEP

PrEP is a new and emerging HIV prevention intervention in which HIV-negative individuals take an antiretroviral (ARV) to reduce their individual risk of acquiring HIV. More here.

PrEP Data to-Date

A number of large-scale trials from a range of populations and in different areas of the world have generated data showing that daily oral TDF/FTC (Truvada) is safe and effective to reduce the risk of HIV infection for HIV-negative people. More here.

Guidance

Guidelines for prescribing and using PrEP are available from a range of groups, including state health departments in the US, the US Centers for Disease Control (CDC) and national-level clinician groups as well as guidelines on international demonstration projects from the World Health Organization. More here.

Implementing PrEP in the “Real World”

Depending on location, communities are at varying stages of implementing PrEP. In the US the Food and Drug Administration (FDA) has approved daily Truvada for HIV prevention, and some communities in the US are exploring how it might best be delivered. Outside of the US, Truvada as PrEP is not approved by local regulators and in most cases remains inaccessible outside of research studies. Country-specific information is being collected. More here.

Cost, Access and Using PrEP

There is a growing body of information on how to access PrEP and how its cost can be covered in the US. There is limited access elsewhere outside of clinical trials or demonstration projects. More here.

Ongoing research

At the same time, additional clinical trial research is ongoing to test new regimens—twice-weekly, for example—and different ARVs, like maraviroc. More here.

Local Advocacy

Advocacy efforts supporting both the PrEP research pipeline and PrEP access for populations most in need are active in areas around the world. More here


Other HIV Prevention Research

PrEP is just one element of the ARV-based and wider biomedical HIV prevention agenda, which include a range of proven approaches and others under study. More here.

Quick Links

What’s new

31 Days of PrEP

Advocate.com is featuring a new article on PrEP each day of the month.


First PrEP hotline for clinicians launched

The Clinician Consultation Center created PrEPline to answer providers’ questions.


POZ devotes October issue to PrEP

Read the articles here.